AACR Project GENIE is an international, pancancer registry, built through data sharing, with the goals of powering precision oncology and clinical decision making, and is driven by openness, transparency, and inclusion.

GENIE aggregates existing and ongoing clinical genotyping efforts from the project participants into a single registry and links this data to select clinical outcomes, providing a real-world dataset that can answer questions about the development and treatment of cancer, including rare cancers and rare variants of common cancers. Access the data at AACR.org/Genie/Data.

AACR Project GENIE® Participants

- Dana-Farber Cancer Institute
- Institut Gustave Roussy, France
- Memorial Sloan Kettering Cancer Center
- The Netherlands Cancer Institute on behalf of the Center for Personalized Cancer Treatment, The Netherlands
- Princess Margaret Cancer Centre, Canada
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
- University of Texas MD Anderson Cancer Center
- Vanderbilt-Ingram Cancer Center
- Children’s Hospital of Philadelphia
- Cancer Research UK Cambridge Centre
- Duke Cancer Institute, Duke University
- Herbert Irving Comprehensive Cancer Center, Columbia University
- Swedish Cancer Institute
- Providence Cancer Institute
- Wake Forest University Health Sciences
- The University of Chicago
- UCSF Helen Diller Family Comprehensive Cancer Center
- Vall d’Hebron Institute of Oncology, Spain
- Yale Cancer Center, Yale University

The GENIE registry powers clinical and translational research in many ways:

- Drug Discovery
- Biomarker Discovery & Validation
- Clinical Trial Feasibility
- Natural History Studies
- Many Others

Learn more at AACR.org/Genie // Questions? Email info@aacrgenie.org // Access the data at AACR.org/Genie/Data